Suppression of motility of human breast cancer cells by human serum after intake of maoto
Suppression of motility of human breast cancer cells by human serum after intake of maoto
复制标题
摄入maoto后人血清对人乳腺癌细胞运动的抑制
DOI：
10.11339/jtm.26.51
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
T. Hanawa
中科院分区：
文献类型：
--
作者：
Hidenori Ito;S. Hyuga;M. Hyuga;Koji Watanabe;T. Tsuda;T. Oikawa;T. Hanawa
我们之前发现，口服maoto的小鼠血清可降低高度转移性小鼠骨肉瘤FBJ-LL细胞的运动性，并且体内口服maoto可抑制FBJ-LL细胞的自发转移。此外，我们报道了添加 maoto 可以阻止人血清诱导的人乳腺癌 MDA-MB-23l 细胞的运动。在这项研究中，我们研究了摄入 maoto 后人血清对 MDA-MB-23l 细胞运动的影响，作为 maoto 作为转移抑制剂临床应用的第一步。对10名健康男性志愿者按常规剂量口服Maoto 3.5天，并在服用maoto之前和摄入后0、0.5、1、2和4小时收集他们的血液。摄入 maoto 后的所有血清均导致 MDA-MB-23l 细胞的运动性降低近 30%，但没有细胞毒性。这些结果表明，maoto 可能是一种适合应用于人类的新型癌症转移抑制剂。
We had previously found that the motility of highly metastatic murine osteosarcoma FBJ-LL cells was decreased by a serum from a mouse orally given maoto and the spontaneous metastasis of FBJ-LL cells was suppressed by oral administration of maoto in vivo. Furthermore, we reported that the human serum-induced motility of human breast cancer MDA-MB-23l cell was prevented by the addition of maoto. In this study, we investigated the effect of human sera after intake of maoto on the motility of MDA-MB-23l cells as a first step to approach for clinical application of maoto as a metastatic inhibitor. Maoto was orally administered to 10 healthy male volunteers at usual dosage for 3.5 days and their bloods were collected before administration of maoto and at 0, 0.5, l, 2 and 4 hours after intake of it. All of the sera after intake of maoto caused almost 30% reductions in the motility of MDA-MB-23l cells without cytotoxicity. These results suggest that maoto may be a novel inhibitor of cancer metastasis suitable for applica tion in humans.
传统东方药物十善太凤糖 (TJ-48) 对小鼠辐射损伤造血恢复的影响。
影响因子：
2.6
作者：
Ohnishi,Y;Yasumizu,R;Fan,HX;Liu,J;Takao-Liu,F;Komatsu,Y;Hosoya,E;Good,RA;Ikehara,S
通讯作者：
Ikehara,S